Skip to main content
. 2021 Apr 13;9:665089. doi: 10.3389/fcell.2021.665089

FIGURE 3.

FIGURE 3

BMI1 inhibits the p38 MAPK pathway. (A) MLTC-1 cells were treated with the indicated concentrations of PTC-209 for 48 h, followed by western blot analysis of p38 MAPK expression. (B) Quantification of (A). (C) MLTC-1 cells were transfected with the indicated concentrations of the pcDNA3.0-Bmi1 plasmid for 48 h, followed by western blot analysis of p38 MAPK expression. (D) Quantification of (C). (E) Western blot analysis of p38 MAPK expression in MLTC-1 cells treated as indicated for 48 h. PTC-209, pcDNA3.0-Bmi1-flag, pcDNA3.0-Bmi1-△NLS2-flag, and N-acetylcysteine (NAC) were used at the concentrations of 5 μM, 1 μg/mL, 1 μg/mL, and 500 μM, respectively. (F) Quantification of (E). (G) Immunofluorescence staining for phospho-p38 in MLTC-1 cells treated as indicated for 48 h. PTC-209, pcDNA3.0-Bmi1-flag, pcDNA3.0-Bmi1-△NLS2-flag, and NAC were used at the concentrations of 5 μM, 1 μg/mL, 1 μg/mL, and 500 μM, respectively. DMSO combined with empty vector (EV) was used as the control. Scale bar, 20 μm. *p < 0.05, **p < 0.01, ***p < 0.001.